Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.77 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.60 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598996 | 0.96 | PIK3CD (0.72) | PIK3CDPIK3CGPIK3C2BPIK3CAPIK3CB | |
| SCHEMBL12599286 | 0.93 | PIK3CG (0.69) | PIK3CDPIK3CGPIK3C2BPIK3CAPIK3CB | |
| SCHEMBL1598125 | 0.93 | PIK3CD (0.66) | PIK3CDPIK3CGPIK3C2BPIK3CAPIK3CB | |
| SCHEMBL1597902 | 0.90 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3C2B | |
| SCHEMBL12599287 | 0.89 | PIK3CG (0.67) | PIK3CDPIK3CGPIK3C2BPIK3CAPIK3CB | |
| SCHEMBL1598104 | 0.89 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL12560389 | 0.87 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3C2BPIK3CAPIK3CB | |
| SCHEMBL1598173 | 0.87 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3C2BPIK3CAPIK3CB | |
| SCHEMBL1598342 | 0.86 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3C2BPIK3CAPIK3CB | |
| SCHEMBL13973987 | 0.86 | PIK3CG (0.65) | PIK3CDPIK3CGPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152277-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | CHEN YI | 2011-06-23 | — | — | US | disclosed |
| US-20110152277-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | CHEN YI | 2011-06-23 | — | — | US | disclosed |
| US-20110152277-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | CHEN YI | 2011-06-23 | — | — | US | disclosed |
| US-7919498-B2 | Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919498-B2 | Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919498-B2 | Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-2132207-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090030002-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030002-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030002-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008118454-A2 | DERIVATIVES OF QUINOLINE OR BENZOPYRAZINE AND THEIR USES FOR THE TREATMENT OF (INTER ALIA) INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES OR VARIOUS KINDS OF CANCER | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118454-A2 | DERIVATIVES OF QUINOLINE OR BENZOPYRAZINE AND THEIR USES FOR THE TREATMENT OF (INTER ALIA) INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES OR VARIOUS KINDS OF CANCER | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152277-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885PIK3CG 54/4885PIK3C2B 60/4885 |
| US-20090030002-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PIK3CD 15/4885PIK3CG 53/4885PIK3C2B 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.